{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T10:41:50Z","timestamp":1793011310690,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11845-025-03879-7","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:35:20Z","timestamp":1739522120000},"page":"455-462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PHLPP and LAMP2 predict favorable treatment response and survival in multiple myeloma patients who receive induction treatment with bortezomib"],"prefix":"10.1007","volume":"194","author":[{"given":"Qingkun","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0968-2793","authenticated-orcid":false,"given":"Xuebing","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"3879_CR1","doi-asserted-by":"publisher","unstructured":"Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK (2022) NCCN Guidelines(R) Insights: multiple myeloma, Version 3.2022. J Natl Compr Canc Netw 20(1):8\u201319. https:\/\/doi.org\/10.6004\/jnccn.2022.0002","DOI":"10.6004\/jnccn.2022.0002"},{"issue":"9","key":"3879_CR2","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV (2024) Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 99(9):1802\u20131824. https:\/\/doi.org\/10.1002\/ajh.27422","journal-title":"Am J Hematol"},{"issue":"9","key":"3879_CR3","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE, 3rd, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS, Non-communicable Disease Global Health Research Group AoPRU","year":"2022","unstructured":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE, 3rd, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS, Non-communicable Disease Global Health Research Group AoPRU (2022) The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol 9(9):e670\u2013e677. https:\/\/doi.org\/10.1016\/S2352-3026(22)00165-X","journal-title":"Lancet Haematol"},{"issue":"23","key":"3879_CR4","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1097\/CM9.0000000000002600","volume":"136","author":"J Liu","year":"2023","unstructured":"Liu J, Liu W, Mi L, Cai C, Gong T, Ma J, Wang L (2023) Burden of multiple myeloma in China: an analysis of the global burden of disease, injuries, and risk factors study 2019. Chin Med J (Engl) 136(23):2834\u20132838. https:\/\/doi.org\/10.1097\/CM9.0000000000002600","journal-title":"Chin Med J (Engl)"},{"key":"3879_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19753","author":"M Mohty","year":"2024","unstructured":"Mohty M, Malard F (2024) Induction prior to autologous haematopoietic cell transplantation in multiple myeloma. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.19753","journal-title":"Br J Haematol"},{"issue":"3","key":"3879_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-022-00645-1","volume":"12","author":"AH Bazarbachi","year":"2022","unstructured":"Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, Mohty M (2022) Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J 12(3):47. https:\/\/doi.org\/10.1038\/s41408-022-00645-1","journal-title":"Blood Cancer J"},{"issue":"8","key":"3879_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(8):1086\u20131107. https:\/\/doi.org\/10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"issue":"5","key":"3879_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327(5):464\u2013477. https:\/\/doi.org\/10.1001\/jama.2022.0003","journal-title":"JAMA"},{"issue":"Suppl 1","key":"3879_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.26512","volume":"97","author":"U Goel","year":"2022","unstructured":"Goel U, Usmani S, Kumar S (2022) Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol 97(Suppl 1):S3\u2013S25. https:\/\/doi.org\/10.1002\/ajh.26512","journal-title":"Am J Hematol"},{"issue":"2","key":"3879_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","volume":"19","author":"P Robak","year":"2019","unstructured":"Robak P, Robak T (2019) Bortezomib for the treatment of hematologic malignancies: 15 years later. Drugs R D 19(2):73\u201392. https:\/\/doi.org\/10.1007\/s40268-019-0269-9","journal-title":"Drugs R D"},{"issue":"1","key":"3879_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010111","volume":"16","author":"G Kozalak","year":"2023","unstructured":"Kozalak G, Butun I, Toyran E, Kosar A (2023) Review on bortezomib resistance in multiple myeloma and potential role of emerging technologies. Pharmaceuticals (Basel) 16(1):111. https:\/\/doi.org\/10.3390\/ph16010111","journal-title":"Pharmaceuticals (Basel)"},{"key":"3879_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110097","volume":"86","author":"KA Lemoine","year":"2021","unstructured":"Lemoine KA, Fassas JM, Ohannesian SH, Purcell NH (2021) On the PHLPPside: emerging roles of PHLPP phosphatases in the heart. Cell Signal 86:110097. https:\/\/doi.org\/10.1016\/j.cellsig.2021.110097","journal-title":"Cell Signal"},{"issue":"6","key":"3879_CR13","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1042\/BST20160170","volume":"44","author":"AT Grzechnik","year":"2016","unstructured":"Grzechnik AT, Newton AC (2016) PHLPPing through history: a decade in the life of PHLPP phosphatases. Biochem Soc Trans 44(6):1675\u20131682. https:\/\/doi.org\/10.1042\/BST20160170","journal-title":"Biochem Soc Trans"},{"key":"3879_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1216131","volume":"13","author":"X Xia","year":"2023","unstructured":"Xia X, Pi W, Chen M, Wang W, Cai D, Wang X, Lan Y, Yang H (2023) Emerging roles of PHLPP phosphatases in lung cancer. Front Oncol 13:1216131. https:\/\/doi.org\/10.3389\/fonc.2023.1216131","journal-title":"Front Oncol"},{"key":"3879_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2147\/OTT.S237343","volume":"13","author":"X Liu","year":"2020","unstructured":"Liu X, Li C, Fu Y, Liu J (2020) PHLPP sensitizes multiple myeloma cells to bortezomib through regulating LAMP2. Onco Targets Ther 13:401\u2013411. https:\/\/doi.org\/10.2147\/OTT.S237343","journal-title":"Onco Targets Ther"},{"issue":"11","key":"3879_CR16","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s41419-021-04251-0","volume":"12","author":"B Guo","year":"2021","unstructured":"Guo B, Xiong X, Hasani S, Wen YA, Li AT, Martinez R, Skaggs AT, Gao T (2021) Downregulation of PHLPP induced by endoplasmic reticulum stress promotes eIF2alpha phosphorylation and chemoresistance in colon cancer. Cell Death Dis 12(11):960. https:\/\/doi.org\/10.1038\/s41419-021-04251-0","journal-title":"Cell Death Dis"},{"key":"3879_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.665045","volume":"11","author":"W Wang","year":"2021","unstructured":"Wang W, Xia X, Chen K, Chen M, Meng Y, Lv D, Yang H (2021) Reduced PHLPP expression leads to EGFR-TKI resistance in lung cancer by activating PI3K-AKT and MAPK-ERK dual signaling. Front Oncol 11:665045. https:\/\/doi.org\/10.3389\/fonc.2021.665045","journal-title":"Front Oncol"},{"issue":"8","key":"3879_CR18","doi-asserted-by":"publisher","first-page":"6510","DOI":"10.1074\/jbc.M110.183087","volume":"286","author":"J Liu","year":"2011","unstructured":"Liu J, Stevens PD, Gao T (2011) mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J Biol Chem 286(8):6510\u20136520. https:\/\/doi.org\/10.1074\/jbc.M110.183087","journal-title":"J Biol Chem"},{"key":"3879_CR19","doi-asserted-by":"publisher","unstructured":"Hubert V, Weiss S, Rees AJ, Kain R (2022) Modulating chaperone-mediated autophagy and its clinical applications in cancer. Cells 11(16). https:\/\/doi.org\/10.3390\/cells11162562","DOI":"10.3390\/cells11162562"},{"issue":"11","key":"3879_CR20","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1080\/15548627.2023.2235196","volume":"19","author":"L Qiao","year":"2023","unstructured":"Qiao L, Hu J, Qiu X, Wang C, Peng J, Zhang C, Zhang M, Lu H, Chen W (2023) LAMP2A, LAMP2B and LAMP2C: similar structures, divergent roles. Autophagy 19(11):2837\u20132852. https:\/\/doi.org\/10.1080\/15548627.2023.2235196","journal-title":"Autophagy"},{"issue":"4","key":"3879_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.seminoncol.2017.10.013","volume":"44","author":"F Alessandrini","year":"2017","unstructured":"Alessandrini F, Pezze L, Ciribilli Y (2017) LAMPs: shedding light on cancer biology. Semin Oncol 44(4):239\u2013253. https:\/\/doi.org\/10.1053\/j.seminoncol.2017.10.013","journal-title":"Semin Oncol"},{"issue":"1","key":"3879_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12935-023-03109-z","volume":"23","author":"Y Guo","year":"2023","unstructured":"Guo Y, Hao Y, Shen L, Du Y, Wang X, Gao L, Feng X, Zhai Y, Liu Z, Xu E, Yang Y, Xi Y, Yang B, Zhang L (2023) TSTA3 overexpression promotes malignant characteristics in LUSC by regulating LAMP2-mediated autophagy and tumor microenvironment. Cancer Cell Int 23(1):285. https:\/\/doi.org\/10.1186\/s12935-023-03109-z","journal-title":"Cancer Cell Int"},{"issue":"8","key":"3879_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/dna.2016.3259","volume":"35","author":"L Bao","year":"2016","unstructured":"Bao L, Lv L, Feng J, Chen Y, Wang X, Han S, Zhao H (2016) miR-487b-5p regulates temozolomide resistance of lung cancer cells through LAMP2-medicated autophagy. DNA Cell Biol 35(8):385\u2013392. https:\/\/doi.org\/10.1089\/dna.2016.3259","journal-title":"DNA Cell Biol"},{"issue":"26","key":"3879_CR24","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from international myeloma working Group. J Clin Oncol 33(26):2863\u20132869. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267","journal-title":"J Clin Oncol"},{"issue":"2","key":"3879_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H, International Myeloma Working G","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H, International Myeloma Working G (2014) IMWG consensus on risk stratification in multiple myeloma. Leukemia 28(2):269\u2013277. https:\/\/doi.org\/10.1038\/leu.2013.247","journal-title":"Leukemia"},{"issue":"1","key":"3879_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H, Niu T, Tong A (2024) Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed 5(1):25. https:\/\/doi.org\/10.1186\/s43556-024-00188-w","journal-title":"Mol Biomed"},{"issue":"2","key":"3879_CR27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/10428194.2016.1190968","volume":"58","author":"W Yu","year":"2017","unstructured":"Yu W, Chen Y, Xiang R, Xu W, Wang Y, Tong J, Zhang N, Wu Y, Yan H (2017) Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance. Leuk Lymphoma 58(2):428\u2013437. https:\/\/doi.org\/10.1080\/10428194.2016.1190968","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"3879_CR28","doi-asserted-by":"publisher","first-page":"2231739","DOI":"10.1080\/16078454.2023.2231739","volume":"28","author":"P Xiao","year":"2023","unstructured":"Xiao P, Chen X, Dong Z, Fan W, Chen Y, Su J, Wang Q, Ma L (2023) BNIP3 overexpression may promote myeloma cell apoptosis by enhancing sensitivity to bortezomib via the p38 MAPK pathway. Hematology 28(1):2231739. https:\/\/doi.org\/10.1080\/16078454.2023.2231739","journal-title":"Hematology"},{"issue":"1","key":"3879_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molcel.2005.03.008","volume":"18","author":"T Gao","year":"2005","unstructured":"Gao T, Furnari F, Newton AC (2005) PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18(1):13\u201324. https:\/\/doi.org\/10.1016\/j.molcel.2005.03.008","journal-title":"Mol Cell"},{"key":"3879_CR30","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1146\/annurev-pharmtox-011112-140338","volume":"54","author":"AC Newton","year":"2014","unstructured":"Newton AC, Trotman LC (2014) Turning off AKT: PHLPP as a drug target. Annu Rev Pharmacol Toxicol 54:537\u2013558. https:\/\/doi.org\/10.1146\/annurev-pharmtox-011112-140338","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"3879_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3978\/j.issn.2218-6751.2011.12.08","volume":"1","author":"LR Pilz","year":"2012","unstructured":"Pilz LR, Manegold C, Schmid-Bindert G (2012) Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? Transl Lung Cancer Res 1(1):26\u201335. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2011.12.08","journal-title":"Transl Lung Cancer Res"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03879-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-03879-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03879-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:14:47Z","timestamp":1745561687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-03879-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3879"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-03879-7","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Review Board of Zibo Central Hospital approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The patients or their guardians provided the informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent."}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}